MEI Pharma announces new clinical data from First-In-Human Study of ME-401

news - MEI pharma

MEI Pharma, the San Diego based oncology company, have today announced new clinical data from a First-In-Human study for ME-401, a next generation oral PI3K delta inhibitor.

The First-In-Human study was conducted using Quotient Sciences’s Translational Pharmaceutics® platform. PK/PD data were collected immediately after each dose allowing for real-time decision making and manufacturing between dose groups.

The data was presented at the AACR Annual Meeting 2016 in New Orleans, in a poster entitled “Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Administration to Healthy Volunteers”.

Access the full MEI Pharma press release here

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.